Resmed stock kpis
Want to see RMD full AI Analyst Report?
Revenue by Segment
Resmed reported revenue by segment of $1.41B in Q1 FY2027, down 3.4% from Q4 FY2026 and up 5.9% year over year. The highest value was $1.46B in Q4 FY2026.
Breaks down overall revenue into specific business segments, providing insight into which parts of the company are performing well and contributing most to the bottom line.
ResMed’s mix is shifting: the Sleep & Breathing franchise remains the revenue backbone with durable product/resupply momentum, while Residential Care Software is the faster-growing, higher‑margin engine—accelerating after recent M&A and product rollouts. Management’s FY27 guidance strips MatrixCare and flags a suspended Astral ventilator program, so reported growth and near‑term EPS will be modestly depressed even as core revenue and gross‑margin expansion persist. In short, underlying recurring software and mask/device replacement trends are sound, but Astral provisions and the MatrixCare divestiture introduce near‑term noise.
RMD Revenue by Segment
| Period | Sleep and Breathing Health Products | Residential Care Software | Total |
|---|---|---|---|
| Q1 FY2027Sep 30, 2026 | $1.26B | $155.01M | $1.41B |
| Q4 FY2026Jun 30, 2026 | $1.29B | $172.00M | $1.46B |
| Q3 FY2026Mar 31, 2026 | $1.26B | $170.89M | $1.43B |
| Q2 FY2026Dec 31, 2025 | $1.26B | $166.90M | $1.42B |
| Q1 FY2026Sep 30, 2025 | $1.17B | $166.10M | $1.34B |
| Q4 FY2025Jun 30, 2025 | $1.18B | $167.00M | $1.35B |
| Q3 FY2025Mar 31, 2025 | $1.13B | $161.20M | $1.29B |
| Q2 FY2025Dec 31, 2024 | $1.13B | $156.50M | $1.28B |
| Q1 FY2025Sep 30, 2024 | $1.07B | $156.77M | $1.22B |
| Q4 FY2024Jun 30, 2024 | $1.07B | $151.90M | $1.22B |
| Q3 FY2024Mar 31, 2024 | $1.05B | $147.96M | $1.20B |
| Q2 FY2024Dec 31, 2023 | $1.02B | $144.95M | $1.16B |
| Q1 FY2024Sep 30, 2023 | $963.04M | $139.28M | $1.10B |
| Q4 FY2023Jun 30, 2023 | $983.50M | $138.60M | $1.12B |
| Q3 FY2023Mar 31, 2023 | $980.12M | $136.78M | $1.12B |
| Q2 FY2023Dec 31, 2022 | $916.98M | $116.76M | $1.03B |
| Q1 FY2023Sep 30, 2022 | $844.44M | $105.85M | $950.29M |
| Q4 FY2022Jun 30, 2022 | $811.60M | $103.10M | $914.70M |
| Q3 FY2022Mar 31, 2022 | $763.36M | $101.14M | $864.50M |
| Q2 FY2022Dec 31, 2021 | $795.84M | $99.03M | $894.87M |
| Q1 FY2022Sep 30, 2021 | $806.50M | $97.52M | $904.01M |
| Q4 FY2021Jun 30, 2021 | $780.30M | $95.80M | $876.10M |
| Q3 FY2021Mar 31, 2021 | $674.93M | $93.84M | $768.77M |
| Q2 FY2021Dec 31, 2020 | $708.18M | $91.83M | $800.01M |
| Q1 FY2021Sep 30, 2020 | $659.80M | $92.14M | $751.94M |
| Q4 FY2020Jun 30, 2020 | $678.90M | $91.50M | $770.40M |
| Q3 FY2020Mar 31, 2020 | $679.89M | $89.56M | $769.46M |
| Q2 FY2020Dec 31, 2019 | $649.50M | $86.70M | $736.20M |
| Q1 FY2020Sep 30, 2019 | $594.20M | $86.90M | $681.10M |
| Q4 FY2019Jun 30, 2019 | $619.80M | $85.20M | $705.00M |
| Q3 FY2019Mar 31, 2019 | $582.30M | $79.90M | $662.20M |

